GV150526 IN TREATMENT OF ACUTE STROKE

这是一项多中心、随机、双盲、安慰剂对照、平行组研究，旨在评价GV 150526或安慰剂在临床诊断为急性卒中的患者中的疗效和安全性。 这种药物是一种有效的甘氨酸拮抗剂。 甘氨酸是N-甲基丙氨酸-d-天冬氨酸（NMDA）受体的共激动剂，用于谷氨酰胺诱导和神经兴奋。 由于谷氨酸对NMDA受体的过度刺激可能在脑缺血期间具有细胞毒性，因此拮抗该受体可能是有益的。 本研究旨在评价急性脑缺血发作和确诊出血性卒中后6小时内给药3个月时的疗效。

This is a multicenter randomized double-blind placebo controlled parallel group study evaluating the efficacy and safety of GV150526 or placebo in patients with a clinical diagnosis of acute stroke. This drug is a potent glycine antagonist. Glycine is a co-agonist of the n-methylanine d aspartate (NMDA) receptor for glutamine-induced and neuroexcitation. Since overstimulation of this NMDA receptor by glutamate may be cytotoxic during cerebral ischemia, antagonism of this receptor may be beneficial. This study is designed to evaluate the efficacy of the drug at 3 months when given within 6 hours of acute ischemic attack and confirmed hemorrhagic stroke.